By Angela Moon
NEW YORK (Reuters) - U.S. stocks rose on Monday, rebounding from the previous session's decline, amid a flurry of merger and acquisition activity in the pharmaceutical sector.
Pharmaceuticals outperformed other sectors after U.S. drugmaker PFIZER (PFE.NY)Inc
Pfizer was the biggest gainer on the Dow Jones industrial average, up 3.9 percent at $31.94.
Separately, Forest Laboratories Inc
Furiex Pharmaceuticals shares jumped 30 percent to $104.12 while Forest Laboratories shares were up 0.4 percent at $90.27.
Adding optimism about the economy, data showed contracts to buy previously owned U.S. homes rose in March for the first time in nine months, in the latest sign that the housing market was stabilizing after a recent wobble.
"Clearly investors are shifting focus to the rich economic calendar we have this week and other events like the FOMC meeting and away from geopolitical concerns," said Peter Cardillo, chief market economist at Rockwell Global Capital in New York.
U.S. President Barack Obama on Monday announced new sanctions against some Russians to stop President Vladimir Putin from fomenting a rebellion in eastern Ukraine, but said he was holding broader measures against Russia's economy "in reserve.
The Dow Jones industrial average <.DJI> rose 110.08 points, or 0.67 percent, to 16,471.54, the S&P 500 <.SPX> gained 8.48 points, or 0.46 percent, to 1,871.88 and the Nasdaq Composite <.IXIC> added 12.654 points, or 0.31 percent, to 4,088.215.
On the benchmark S&P index, financial stocks were among the worst performers, with the sector <.SPSY> down 0.2 percent. Bank of America shares were down 4.6 percent at $15.22 while Goldman Sachs
Bank of America Corp
On the Nasdaq, Amazon.com Inc
Comcast Corp
Charter Communications shares rose 7.3 percent to $139.56 after the company also reported a 15 percent jump in first-quarter revenue.
(Editing by Bernadette Baum)
Relacionados
- (Amp) AstraZeneca responde a Pfizer que confía en generar valor para sus accionistas como firma independiente
- Economía.- (Amp) AstraZeneca responde a Pfizer que confía en generar valor para sus accionistas como firma independiente
- Pfizer, interesada en adquirir AstraZeneca por unos 100.000 millones dólares
- Pfizer confirma que está interesada en hacerse con el control de AstraZeneca
- Pfizer confirma su interés por la británica AstraZeneca